Lilly Seaport Innovation Center (LSC), formerly known as Lilly Institute for Genetic Medicine, is a research and development facility dedicated to advancing RNA and DNA-based therapies in the Seaport Innovation District of Greater Boston, Massachusetts. The facility is used to discover new drug targets to treat diseases including diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain. LSC is the central hub for Eli Lilly’s genetic medicine initiatives and hosts the company’s first East Coast Lilly Gateway Labs.
Developed with an investment of approximately $700m, the facility was opened in August 2024. LSC accommodates 500 researchers and experts working in the fields of biology, chemistry and data science, and 200 employees from the companies within Lilly Gateway Labs. Location The facility is located opposite Fort Point Channel in the 12-storey life science building 15 Necco developed and operated by US-based real estate companies Alexandria Real Estate Equities and partner National Development at 15 Necco Street in the Boston Seaport.
15 Necco includes office, life science and research and development spaces, along with retail and a new public park adjacent to the building. The office and lab space of the building is fully leased to Eli Lilly. The building sits on a 2.
7-acre (1 hectare) site in the Fort Point neighbourhood. It is located next to Cambridge’s Kendall Square and can be accessed from several major transportation hubs. Lilly Seapor.